Archive: 2 10 2020
ATMPs and CAR-T: the uptake challenge
![HemAffairs ATMPs and CAR T](/assets/Uploads/HemAffairs-ATMPs-and-CAR-T__ScaleMaxWidthWzY0MF0.png)
Advanced therapy medicinal products (ATMPs) are a game changer for improving the lives of patients with severe to life-threatening diseases. Yet, despite fast-paced innovation in the field, few ATMPs have reached the EU market and benefited patients. The challenges facing their adoption by health systems are complex. A test case is the uptake of CAR T-cell therapy; what are the hurdles and what action is needed from stakeholders?
EU health policy: limited scope, high ambition
![HemAffairs EU health policy](/assets/Uploads/HemAffairs-EU-health-policy__ScaleMaxWidthWzY0MF0.png)
While health policy remains the primary responsibility of Member States, in many areas the added value of EU-level collaboration and harmonization has increased. EU initiatives in health have shown a mixed record in terms of impact, but hopes are high for the latest one, the ambitious Europe’s Beating Cancer Plan.